SEC Form SC 13G/A filed by Inovio Pharmaceuticals Inc. (Amendment)
$INO
Medical/Dental Instruments
Health Care
Save time and jump to the most important pieces.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 5/14/2024 | $20.00 | Overweight | Stephens |
| 1/25/2024 | $4.00 | Perform → Outperform | Oppenheimer |
| 11/9/2022 | Buy → Hold | Maxim Group | |
| 11/1/2022 | $2.00 | Neutral → Underperform | BofA Securities |
| 7/19/2022 | $5.00 → $4.00 | Sector Perform | RBC Capital Mkts |
| 5/11/2022 | Outperform → Perform | Oppenheimer | |
| 3/2/2022 | $6.00 → $5.00 | Sector Perform | RBC Capital |
| 1/21/2022 | $8.00 → $10.00 | Underperform → Neutral | B of A Securities |
Mr. Egge brings over 25 years of biopharmaceutical experience building commercial organizations and successfully launching novel therapeutic products INOVIO poised to become a commercial-stage company with plans to submit a Biologics License Application for INO-3107 in second half of 2024 under U.S. Food and Drug Administration's Accelerated Approval Pathway PLYMOUTH MEETING, Pa., July 2, 2024 /PRNewswire/ -- INOVIO (NASDAQ:INO), a biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from HPV-related diseases, cancer, and infectious diseases, today announced the appointment of Steven Egge as Chief Commercial Officer. Mr. Egge will le
PLYMOUTH MEETING, Pa., June 27, 2022 /PRNewswire/ -- INOVIO (NASDAQ:INO), a biotechnology company focused on developing and commercializing DNA medicines to help protect people from infectious diseases and treat people with cancer and HPV-associated diseases, today announced the appointment of Dr. Michael Sumner, MB BS, MBA, as Chief Medical Officer (CMO). Dr. Sumner will oversee INOVIO's clinical-stage pipeline of DNA medicines, global clinical development, clinical operations and biostatistics efforts, as well as regulatory affairs, pharmacovigilance and medical affairs. He will serve on the company's executive leadership team and will report to INOVIO's President and Chief Executive Offic
Dr. Shea brings more than 25 years of leadership and industry expertise in life sciences and biotech PLYMOUTH MEETING, Pa., May 10, 2022 /PRNewswire/ -- INOVIO (NASDAQ:INO), a biotechnology company focused on developing and commercializing DNA medicines to help protect people from infectious diseases and treat people with cancer and HPV-associated diseases, today announced the appointment of Jacqueline Shea, Ph.D., as President and Chief Executive Officer (CEO) of INOVIO, effective immediately. Dr. Shea succeeds Dr. J. Joseph Kim in these roles. Dr. Kim has also resigned as a member of the INOVIO board of directors, and the board intends to appoint Dr. Shea as a director following INOVIO'
HC Wainwright & Co. analyst Raghuram Selvaraju reiterates Inovio Pharmaceuticals (NASDAQ:INO) with a Neutral and maintains $15 price target.
Award recognizes the potential for INO-3107 to be the first therapeutic option in the United Kingdom for patients suffering from Recurrent Respiratory Papillomatosis (RRP)PLYMOUTH MEETING, Pa., July 11, 2024 /PRNewswire/ -- INOVIO (NASDAQ:INO), a biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from HPV-related diseases, cancer, and infectious diseases, today announced that its lead DNA medicine candidate, INO-3107, has been designated an innovative medicine as part of the U.K.'s Innovative Licensing and Access Pathway (ILAP). The designation, called an Innovation Passport, was granted by the ILAP Steering Group to INO-3107 for th
Stephens initiated coverage of Inovio Pharma with a rating of Overweight and set a new price target of $20.00
Oppenheimer upgraded Inovio Pharma from Perform to Outperform and set a new price target of $4.00
Maxim Group downgraded Inovio Pharma from Buy to Hold
4 - INOVIO PHARMACEUTICALS, INC. (0001055726) (Issuer)
4 - INOVIO PHARMACEUTICALS, INC. (0001055726) (Issuer)
4 - INOVIO PHARMACEUTICALS, INC. (0001055726) (Issuer)
PLYMOUTH MEETING, Pa., Aug. 8, 2024 /PRNewswire/ -- INOVIO (NASDAQ:INO), a biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from HPV-related diseases, cancer, and infectious diseases, today announced its financial results for the second quarter of 2024 and provided an update on recent company developments. "We continue to make progress with our lead candidate, INO-3107, which has the potential to significantly improve the lives of patients with RRP. We expect all non-device related elements of our BLA package to be
PLYMOUTH MEETING, Pa., July 25, 2024 /PRNewswire/ -- INOVIO (NASDAQ:INO), a biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from HPV-associated diseases, cancer, and infectious diseases, today announced that second quarter 2024 financial results will be released after the market close on August 8, 2024. Following the release, INOVIO will host a live conference call and webcast at 4:30 p.m. ET to discuss financial results and provide a general business update. The live webcast will be available online at http://ir.i
PLYMOUTH MEETING, Pa., April 29, 2024 /PRNewswire/ -- INOVIO (NASDAQ:INO), a biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from HPV-associated diseases, cancer, and infectious diseases, today announced that first quarter 2024 financial results will be released after the market close on May 13, 2024. Following the release, INOVIO will host a live conference call and webcast at 4:30 p.m. ET to discuss financial results and provide a general business update. The live webcast will be available online at http://ir.ino
SC 13G - INOVIO PHARMACEUTICALS, INC. (0001055726) (Subject)
SC 13G/A - INOVIO PHARMACEUTICALS, INC. (0001055726) (Subject)
SC 13G/A - INOVIO PHARMACEUTICALS, INC. (0001055726) (Subject)
PLYMOUTH MEETING, Pa., Nov. 6, 2024 /PRNewswire/ -- INOVIO (NASDAQ:INO), a biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from HPV-related diseases, cancer, and infectious diseases, today announced that it will present at the following scientific conferences: 36th International Papillomavirus Conference (Edinburgh, UK; November 12-15) Presentation and poster by Dr. Matthew Morrow, VP of Translational Sciences Abstract Title: Treatment of recurrent respiratory papillomatosis with INO-3107 induces significant enric
American Association for Cancer Research (AACR) Special Conference: Tumor Immunology and Immunotherapy: New immunology data showed ability of INO-3107 to induce an antigen-specific T cell response against HPV-6 and HPV-11 and drive recruitment of T cells into airway tissues and papillomaInternational Society of Vaccines Conference: Full safety and efficacy data from Phase 1/2 clinical study in patients with Recurrent Respiratory Papillomatosis (RRP) indicated that INO-3107 was well tolerated and immunogenic; 81% of patients in the trial required fewer surgeries post-treatment when compared to baselinePLYMOUTH MEETING, Pa., Oct. 21, 2024 /PRNewswire/ -- INOVIO (NASDAQ:INO), a biotechnology co
PLYMOUTH MEETING, Pa., Oct. 2, 2024 /PRNewswire/ -- INOVIO (NASDAQ:INO), a biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from HPV-related diseases, cancer, and infectious diseases, today announced that it has made equity grants to certain employees under its 2022 Inducement Plan (the "Inducement Plan"). The Compensation Committee of INOVIO's Board of Directors has approved the awards of restricted stock units ("RSU"s) covering an aggregate of 1,526 shares of common stock and options to purchase an aggregate of 1,
424B5 - INOVIO PHARMACEUTICALS, INC. (0001055726) (Filer)
8-K - INOVIO PHARMACEUTICALS, INC. (0001055726) (Filer)
8-K - INOVIO PHARMACEUTICALS, INC. (0001055726) (Filer)